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Bevacizumab is a humanized antibody that blocks vascular endothelial growth factor and is of great value for the
treatment of advanced cancer. Several adverse effects following its administration have been reported. To date, only 8 cases of
osteonecrosis of the jaws associated with bevacizumab (without any association with bisphosphonates) have been reported.
The aim of this article was to describe an original case of bevacizumab-related osteonecrosis of the jaw. A 61-year-old man
diagnosed with advanced renal cell carcinoma was undergoing treatment with intravenous bevacizumab and temsirolimus
when he spontaneously developed mandible osteonecrosis, which resolved after 3 months of conservative management. The
present case reinforces recent speculation that the anti-angiogenic properties of bevacizumab may represent a potential new
source of osteonecrosis of the jaws in patients undergoing cancer treatment. Multidisciplinary teams in cancer care should be
aware of the possible association between osteonecrosis of the jaw and bevacizumab therapy. (Oral Surg Oral Med Oral Pathol
Oral Radiol 2013;115:e32-e36)With the evolution of cancer therapy protocols, atten-
tion is being given to the development of more precise
therapies that target tumor tissue and reduce toxicity to
non-neoplastic (normal) tissues. Molecular targeted
therapies have been developed in order to control the
growth and survival of malignant cells by interfering
with speciﬁc molecular routes involved in carcinogen-
esis. However, recent publications investigating the
safety of cancer target therapies have indicated that oral
complications remain an important issue in contempo-
rary cancer treatment.1
Bevacizumab is a recombinant humanized mono-
clonal immunoglobulin antibody designed to selectively
bind and inhibit the biological activity of all isoforms of
human vascular endothelial growth factor-A (VEGF-A).
This was the ﬁrst clinically available angiogenesis
inhibitor and is mainly used for the treatment of
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e32brain and non-small cell lung cancers.2,3 It is also used
to inhibit blood vessel proliferation in the retina for the
treatment of macular degeneration.4
In conjunction with its promising anti-neoplastic
activity, a series of side effects have been reported in
patients undergoing bevacizumab therapy. Hyperten-
sion, epistaxis, gastrointestinal hemorrhage-perforation,
bleeding events, proteinuria, leucopenia, diarrhea,
asthenia, thromboembolic events, impaired wound
healing and nasal septum perforation are some
examples.3,5,6
Angiogenesis and osteonecrosis of the jaws (ONJ)
have been linked by case reports of ONJ occurring in
patients treated with anti-tumor therapies targeting
VEGF-A.7 ONJ after intravenous administration of
bevacizumab for the treatment of cancer was ﬁrst
described by Estilo et al. in 2008.8 Since then, limited
data concerning the risk of osteonecrosis in patients
taking bevacizumab have been published (Table I).9-15
Thus, the purpose of this manuscript is to report
an additional case of ONJ related to the use of
bevacizumab in order to highlight a potential newStatement of Clinical Relevance
Drug-related osteonecrosis of the jaws (DRONJ) is
a signiﬁcant complication, which can affect patients
undergoing treatment with bisphosphonates, anti-
resorptive agents, and anti-angiogenic factors. Bev-
acizumab and temsirolimus may represent a new
source of DRONJ in patients undergoing target
cancer therapies.
Table I. Previously reported cases of osteonecrosis of the jaws related to the use of bevacizumab (without the association with bisphosphonates)
Reference Age Gender Diagnosis Treatment ONJ site
Dental
predisposing
factor ONJ treatment ONJ outcome
Estilo et al., 20088 51 F Breast ductal
carcinoma
Mastectomy, doxorubicin,
cyclophosphamide,
letrozole, albumin-bound
nanoparticle-paclitaxel,
chest wall radiation,
capecitabine and
bevacizumab
Posterior lingual mandible
(molar area)
None Chlorhexidine oral rinse,
bevacizumab discontinued
Resolution in a few
weeks. A new area
of exposed bone
appeared
Estilo et al., 20088 33 F Glioblastoma
multiforme
(brain)
Surgical resection, radiation
therapy, temozolomide and
bevacizumab
Posterior buccal mandible
(molar area)
None NA Spontaneous
resolution
Greuter et al., 20089 63 F Breast cancer Liposomal doxorubicin and
bevacizumab
Posterior maxilla (molar
area)
Tooth
extraction
Surgical treatment Resolution
Serra et al., 200910 NA (middle
aged)
M Lung cancer Pneumonectomy, lymph node
ablation and bevacizumab
Posterior mandible Tooth
extraction
Amoxicillin, clavulanate and
chlorhexidine oral rinses
Remission of
infection,
persistence of ONJ
Guarneri et al., 201012 NA NA Breast cancer Docetaxel in combination
with bevacizumab
Mandible None Surgical treatment and
medication (not described)
NA
Guarneri et al., 201012 NA NA Breast cancer Docetaxel in combination
with bevacizumab
NA None Surgical treatment and
medication (not described)
NA
Dis¸el et al., 201214 51 M Colon
carcinoma
Fluorouracil, leucovorin,
oxaliplatin, and
bevacizumab
Posterior buccal
mandible, molar area
None Bone curettage NA
Hopp et al., 201215 58 M Retinal vascular
thrombosis
Bevacizumab e intravitreal
administration
Posterior lingual mandible
(molar area)
None Bone curettage Resolution in 3 weeks
Current case 61 M Renal cell
carcinoma
Bevacizumab and
temsirolimus
Posterior lingual mandible
(molar area)
None Chlorhexidine oral rinse Resolution
F, female; M, male; NA, not available; ONJ, osteonecrosis of the jaws.
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e34 Santos-Silva et al. June 2013source of ONJ in patients undergoing modern protocols
of cancer treatment who have not previously been
exposed to bisphosphonates.Fig. 1. Intra-oral examination revealed a 1.0  1.0 cm area of
bone exposed on the left lingual surface of the posterior
mandible compatible with ONJ associated with bevacizumab.
Fig. 2. Panoramic radiograph examination failed to demon-
strate gross evidence of bone destruction affecting the left
posterior mandible. However, there was a discreet discontin-
uation of the left external oblique line of the mandible asso-
ciated with small and ill-deﬁned radiolucent and radiopaque
images.CASE REPORT
A 61-year-old man complaining of a painful lesion on
his left mandible for about 1 month was referred to the
Service of Dental Oncology of the Instituto do Câncer
do Estado de São Paulo, Brazil. The patient’s medical
history included systemic arterial hypertension and he
had been taking 25 mg of captopril twice daily for the
past 5 years and 25 mg of hydrochlorothiazide once
a day for the past 2 years. He reported drinking alcohol
only rarely and had smoked about 20 cigarettes a day
for the past 20 years. The patient denied any previous
history of diabetes or immunosuppression. In addition,
the patient was diagnosed with renal cell carcinoma in
2007 and managed by partial nephrectomy; however,
positive surgical margins were detected in the ﬁnal
pathologic examination and thus the patient was
subsequently submitted to radical nephrectomy. Histo-
logical evaluation of the second surgical specimen
provided the ﬁnal diagnosis of a clear cell carcinoma. In
2009, during continuous medical follow-up, the patient
was diagnosed with metastatic renal cell carcinoma in
the mediastinal and retroperitoneal lymph nodes.
Following the diagnosis of advanced renal cell carci-
noma, the patient was included in an open-label phase
III clinical trial (INTORACT e ClinicalTrials.gov,
NCT00631371), and was treated with intravenous
bevacizumab (10 mg/kg every 2 weeks) and temsir-
olimus (25 mg intravenous weekly).
After 55 weeks of treatment with the combination of
bevacizumab and temsirolimus, the patient reported
diffuse and spontaneous pain in the left posterior
mandible. Clinical examination revealed a 1.0  1.0 cm
area of bone exposed on the left lingual surface of the
posterior mandible (Figure 1). The adjacent oral
mucosa was normal and there was no sign of infection,
bleeding or purulent discharge. There were no teeth in
the posterior mandible and other parts of the oral cavity/
teeth were unremarkable. Radiographic examination
(mandible panoramic radiograph) failed to demonstrate
gross evidence of bone destruction. However, there was
a discrete discontinuation of the left external oblique
line of the mandible associated with small and ill-
deﬁned radiolucent and radiopaque images (Figure 2).
On the other hand, computed tomography of the
mandible revealed loss of integrity and erosion of the
underlying cortical bone associated with the lesion
(Figure 3). The patient denied any other relevant
medical or dental history such as recent tooth extrac-
tion, oral traumatic events, head and neck radiotherapy
or the use of bisphosphonates.The clinical features of bone exposure in the
mandible were compatible with ONJ, and the initial
conservative therapeutic approach was based on oral
chlorhexidine (0.12%) rinses 3 times a day. Bev-
acizumab and temsirolimus infusions were temporarily
stopped. The patient was kept in close follow-up and
the pain resolved after 1 month. Nevertheless, mandible
bone exposure was still present and oral rinses with
chlorhexidine were maintained. After 3 months, the
bone was no longer exposed. Based on the clinical
history and features, the presumptive diagnosis was
ONJ associated with the use of bevacizumab. Bev-
acizumab and temsirolimus were resumed after ONJ
resolution, and no other ONJ episodes were diagnosed.
DISCUSSION
Angiogenesis plays a crucial role in tumor growth,
invasion, and metastasis. In this context, VEGF is
a family of cytokines that are overexpressed in various
human tumors and perform essential functions in tumor
angiogenesis. In addition, overexpression of VEGF has
Fig. 3. Conventional CT scan of the mandible obtained under bone window. A, Axial section and B, Coronal section revealed loss
of integrity and diffuse erosion of the lingual cortical bone.
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progression. Bevacizumab is a recombinant, humanized
monoclonal antibody that binds to VEGF-A and
consequently inhibits angiogenesis.8,16 In February
2004, bevacizumab became the ﬁrst angiogenesis
inhibitor approved by the United States Food and Drug
Administration (FDA) for clinical use in patients with
colorectal cancer and has subsequently received
approval for use in patients with non-small-cell lung
cancer and metastatic breast cancer.2,3,8,16 Recently, the
FDA revoked the accelerated approval of the breast
cancer indication for bevacizumab by stating that its use
for metastatic breast cancer did not show a beneﬁt in
terms of a delay in the growth of tumors that would
overcome its potentially life-threatening complications.
A range of severe complications associated with the
intravenous administration of bevacizumab has been
reported, including hypertension, gastrointestinal
hemorrhage-perforation, nasal septum perforation,
bleeding events, thromboembolic events, proteinuria,
leucopenia, diarrhea, asthenia and impaired wound
healing.3,5,6
ONJ is a potentially dangerous bone disease that
affects the maxilla and the mandible, causing necrosis to
areas of jawbone. It generally occurs as a result of
ischemia (avascular osteonecrosis). Several causes of
ONJ have been reported over the last few decades,
including the chronic use of systemic corticosteroids and
toxicity from heavy metals (lead and cadmium), among
others. In recent years, an increased number of cases of
ONJ have been associated with bisphosphonates when
used in higher doses for the treatment of some cancers
(e.g., metastatic bone lesions of multiple myeloma and
solid cancers), and less often, when used in lower doses
for the prevention of osteoporosis. The main risk factors
for bisphosphonate-related ONJ include subsequent
dental procedures or local trauma, including oral surgical
procedures, such as extractions, periapical surgery, and
periodontal surgery involving osseous tissue.17 Eight
cases of ONJ following the administration ofbevacizumab and not associated with concurrent use of
bisphosphonates have been reported in the literature
since 2008.8-10,12-15 Furthermore, a number of case series
describing ONJ in patients undergoing treatment in
association with anti-angiogenic agents, including bev-
acizumab, and bisphosphonates have recently been
published.11,12,18-20 Recently, the ﬁrst case of non-
intravenous bevacizumab-induced ONJ was reported in
a patient who was treated with the intravitreal adminis-
tration of bevacizumab over 2 years for retinal vascular
thrombosis.15
Our patient did not have a history of oral or intra-
venous bisphosphonate therapy, head and neck radio-
therapy or other ONJ-predisposing factors. It is also
worth mentioning that our patient denied oral trauma or
recent dental surgery/extraction. Remarkably, both of
the original described cases of ONJ associated with
bevacizumab reported by Estilo et al.8 as well as 4 out
of 8 cases published to date14,15 also developed spon-
taneously in the mandible and self-resolved a few
weeks after diagnosis. The current case report, and the
other published cases of bevacizumab-related
ONJ8-10,12 together with 2 previously reported cases of
nasal septum perforation in patients treated with bev-
acizumab5,6 reinforce the speculation that these events
may be related to the anti-angiogenic properties of this
drug.
The relatively fast response to conservative treatment
observed in the current casewas probably due to the early
diagnosis. Similarly, all the other previously published
bevacizumab-related ONJ were diagnosed at early stages
and presented favorable outcome after conservative or
surgical management.8-10,12-15 Although bisphospho-
nates and bevacizumab-related ONJ may present simi-
larly from a clinical point of view18 it is still too early to
make comparisons between bisphosphonate- and bev-
acizumab-related ONJ regarding time of onset, clinical
progress and outcome.
Following the evidence that VEGF is essential for
osteogenic differentiation and bone formation, it has
ORAL MEDICINE OOOO
e36 Santos-Silva et al. June 2013been hypothesized that the anti-angiogenic properties of
bevacizumab could compromise microvessel integrity in
the jaw and lead to subclinical compromise of the bone.8
Similarly, impaired angiogenesis-dependent wound
healing has been hypothesized to explain how bev-
acizumab could cause oral mucosal breakdown and
expose necrotic jawbone.8 Likewise, other well-known
effects of bevacizumab, such as the regression of existing
microvessels (which helps arrest tumor growth and
reduce tumor size), the “normalization” of surviving
mature vasculature and inhibition of vessel growth and
neovascularization, may play a role in the multifactorial
etiopathogenesis of bevacizumab-related ONJ.8,18
Recent studies have indicated a similar association of
ONJ with angiogenesis inhibitors used in cancer treat-
ment, other than bisphosphonates and bevacizumab.
Denosumab, an osteoclast inhibitor used in advanced
osteoporosis and bone metastases, is also able to cause
ONJ.21 Similarly, recent case reports have demonstrated
an association between ONJ and the oral anti-angiogenic
tyrosine-kinase inhibitor sunitinib, already approved for
the treatment of renal cell cancer, neuroendocrine
tumors and gastrointestinal stromal tumors.22,23 Despite
their distinct mechanisms of action, all the mentioned
agents lead to alterations in bone metabolism and turn-
over. Although cases of ONJ associated with bev-
acizumab, denosumab and sunitinib treatment remain
uncommon, the number of published reports seems to be
growing, which emphasizes the fact that patients under
treatment with these drugs may be aware of an increased
risk of the development of ONJ.21-23
Apparently, this is the ﬁrst report of ONJ in a patient
treated with the combination of bevacizumab and tem-
sirolimus (a mammalian target of rapamycin [mTOR]
inhibitor). To the best of our knowledge, temsirolimus
alone has never been associated with ONJ, and the
possibility of temsirolimus acting as a cofactor cannot
be ruled out. Multidisciplinary teams in cancer care
should be aware of this potential new etiology of ONJ.
REFERENCES
1. Watters AL, Epstein JB, Agulnik M. Oral complications of tar-
geted cancer therapies: a narrative literature review. Oral Oncol.
2011;47:441-448.
2. Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of
efﬁcacy and safety of bevacizumab in combination with chemo-
therapy or erlotinib compared with chemotherapy alone for
treatment of recurrent or refractory nonesmall-cell lung cancer.
J Clin Oncol. 2007;25:4743-4750.
3. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C,
Siebert U. Safety of bevacizumab in patients with advanced
cancer: a meta-analysis of randomized controlled trials. Oncolo-
gist. 2010;15:1179-1191.
4. Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS. Off-label
use of bevacizumab for the treatment of age-related macular
degeneration: what is the evidence? Drugs Aging. 2009;26:295.5. Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum
perforation. Oncologist. 2006;11:85-86.
6. Traina TA, Norton L, Drucker K, Singh B. Nasal septum perfo-
ration in a bevacizumab-treated patient with metastatic breast
cancer. Oncologist. 2006;11:1070-1071.
7. Van Poznak C. Osteonecrosis of the jaw and bevacizumab
therapy. Breast Cancer Res Treat. 2010;122:189-191.
8. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw
related to bevacizumab. J Clin Oncol. 2008;20:4037.
9. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-
associated osteonecrosis of the jaw. Ann Oncol. 2008;19:2091.
10. Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tetè S,
Dolci M. Bevacizumab-related osteonecrosis of the jaw. Int J
Immunopathol Pharmacol. 2009;22:1121.
11. Christodoulou C, Pervena A, Klouvas G, et al. Combination of
bisphosphonates and anti-angiogenic factors induces osteonec-
rosis of the jaw more frequently than bisphosphonates alone.
Oncology. 2009;76:209.
12. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteo-
necrosis of the jaw: incidence and association with bisphospho-
nate therapy in three large prospective trials in advanced breast
cancer. Breast Cancer Res Treat. 2010;122:181-188.
13. Wynn RL. Bevacizumab (avastin): an anti-angiogenic drug asso-
ciated with osteonecrosis of the jaw. Gen Dent. 2011;59:410-413.
14. Dis¸el U, Bes¸en AA, Özyılkan Ö, Er E, Canpolat T. A case report
of bevacizumab-related osteonecrosis of the jaw: old problem,
new culprit. Oral Oncol. 2012;48:e2-e3.
15. Hopp RN, Pucci J, Santos-Silva AR, Jorge J. Osteonecrosis after
administration of intravitreous bevacizumab. J Oral Maxillofac
Surg. 2012;70:632-635.
16. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for
the treatment of solid malignancies. Clin Ther. 2006;28:1779.
17. Woo SB, Hellstein JW, Kalmar JR. Systematic review:
bisphosphonates and osteonecrosis of the jaw. Ann Intern Med.
2006;144:753-761.
18. Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA,
O’Connor TL. Osteonecrosis of the jaw: dental outcomes in
metastatic breast cancer patients treated with bisphosphonates
with/without bevacizumab. Clin Breast Cancer. 2011;11:
252-257.
19. Francini F, Pascucci A, Francini E, et al. Osteonecrosis of the jaw
in patients with cancer who received zoledronic acid and bev-
acizumab. J Am Dent Assoc. 2011;142:506-513.
20. Katsenos S, Christophylakis C, Psathakis K. Osteonecrosis of the
jaw in a patient with advanced non-small-cell lung cancer
receiving bevacizumab. Arch Bronconeumol. 2012;48:218-219.
21. Diz P, López-Cedrún JL, Arenaz J, Scully CJ. Denosumab-related
osteonecrosis of the jaw. Am Dent Assoc. 2012;143:981-984.
22. Hoefert S, Euﬁnger H. Sunitinib may raise the risk of
bisphosphonate-related osteonecrosis of the jaw: presentation of
three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2010;110:463-469.
23. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis
of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral
Radiol. 2012;113:e1-e3.Reprint requests:
Alan Roger Santos-Silva, DDS, PhD
Piracicaba Dental School, University of Campinas (UNICAMP)
Oral Diagnosis Department (Semiology Area)
Avenida Limeira, 901, Caixa Postal 52
CEP: 13414-903, Piracicaba e SP, Brazil
alanroger@fop.unicamp.br
